Investors File Securities Class Action Against PROCEPT BioRobotics

The complaint alleges that PROCEPT violated the Securities Exchange Act by inflating revenue through aggressive discounting tactics. These actions purportedly pulled future sales forward, resulting in an artificial inventory surplus that was not disclosed to the market. Consequently, the lawsuit claims that the company’s public statements throughout the two-year class period were materially misleading.

Shareholders seeking to participate in the litigation must act by September 22, 2026. While the DJS Law Group is encouraging investors to contact them regarding lead plaintiff appointments, the firm notes that such a designation is not a prerequisite for recovering potential losses. The case centers on transparency failures that allegedly obscured the company's true financial health from the investing public.